Key result
Biophen DiXaI showed a strong linear correlation (r=0.99) with spiked rivaroxaban concentrations, indicating its utility for monitoring anticoagulation activity and evaluating bleeding risk.
Why the study?
How do routine coagulation assays correlate with rivaroxaban concentrations and its bleeding risk?
Observational
How do routine coagulation assays correlate with rivaroxaban concentrations and its bleeding risk?
Effect estimate: correlation coefficient 0.99
Biophen DiXaI can be used as a quantitative method to monitor the anticoagulation activity of rivaroxaban, while PT (Thrombosis S) can serve as a rough monitoring method.
No takes yet. Share an insight, caveat, or question.
Supports Biophen DiXaI evaluation for rivaroxaban monitoring in research; leaves open clinical utility pending patient studies.
Zhang et al. (2016) conducted an observational in Patients treated with rivaroxaban. Rivaroxaban was evaluated on Correlation between measured and spiked concentrations of rivaroxaban (correlation coefficient 0.99). Biophen DiXaI showed a strong linear correlation (r=0.99) with spiked rivaroxaban concentrations, indicating its utility for monitoring anticoagulation activity and evaluating bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: